Moderna Inc. ($MRNA) Stock Forecast: Down 5.0% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its innovative mRNA technology, primarily focusing on vaccines and therapies for various diseases. The stock displayed significant bearish activity in the market recently.

Why is Moderna Inc. going down?

MRNA stock is down 5.0% on Jun 9, 2026 15:26

• The authorization granted to Moderna and the University of Oxford to initiate a Phase 1/2 study on an mRNA cancer vaccine for individuals with Lynch syndrome did not appear to have a positive impact on the stock price. This lack of significant effect might suggest that investors were anticipating more substantial news to influence the market.
• The selling of shares by Moderna's Chief Legal Officer, Shannon Thyme Klinger, could have contributed to the negative market sentiment. This insider trading activity might have been perceived as a signal of uncertainty regarding the company's future outlook.
• Despite noteworthy advancements in cancer vaccine trials and the appointment of a seasoned professional from Procter & Gamble to Eikon Therapeutics' Board of Directors, the focus on the Chief Legal Officer's share selling could have overshadowed these developments. This focus possibly swayed the stock's downward trajectory.
• An analysis hinting at Moderna's stock being potentially overvalued by InvestingPro may have further fueled the bearish sentiment. This suggestion might have prompted investors to reassess their positions, potentially triggering a sell-off.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Moderna and the University of Oxford have received UK authorization to begin a Phase 1/2 study of mRNA-4194, an investigational mRNA cancer vaccine for individuals with Lynch syndrome. This inherited condition significantly increases cancer risk, and the vaccine aims to prevent cancer development by generating immune responses against early cancer growth. The trial, funded by Moderna and sponsored by the University of Oxford, is part of a broader strategic partnership with the UK Government to advance mRNA research and enhance pandemic preparedness.

https://investingnews.com/moderna-and-the-university-of-oxford-receive-uk-authorization-to-begin-phase-1-2-study-of-investigational-mrna-cancer-vaccine-for-people-with-lynch-syndrome/

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Moderna and the University of Oxford have received UK authorization to commence a Phase 1/2 study for an investigational mRNA cancer vaccine, mRNA-4194, targeting individuals with Lynch Syndrome. This inherited condition significantly increases cancer risk, and the vaccine aims to prevent cancer development by training the immune system to recognize early cancer changes. The first patients are expected to be dosed this summer, with the second phase expanding across multiple UK centers in 2027.

https://finance.yahoo.com/sectors/healthcare/articles/moderna-university-oxford-receive-uk-230100601.html

Inherited cancer risk for 1 in 300: Moderna mRNA trial targets Lynch syndrome

Moderna and the University of Oxford have received UK authorization to begin a Phase 1/2 clinical trial for an investigational mRNA cancer vaccine (mRNA-4194) targeting individuals with Lynch syndrome. This trial is Moderna's first cancer prevention program, aiming to assess the vaccine's safety, immune response, and optimal dosing. Lynch syndrome is a common inherited condition significantly increasing cancer risk, and the collaborative effort seeks to prevent cancer development by leveraging mRNA technology to train the immune system.

https://www.stocktitan.net/news/MRNA/moderna-and-the-university-of-oxford-receive-uk-authorization-to-2f3gcbca6rd7.html

Eikon Signals Commercial Ambition, Tapping P&G Veteran For Board Seat

Eikon Therapeutics has appointed Ma. Fatima D. Francisco, a veteran from Procter & Gamble, to its Board of Directors, signaling a strategic shift towards commercialization beyond pure R&D. This move comes after a recent $381 million IPO and promising clinical trial results for its lead cancer therapy, EIK1001. The appointment aims to leverage Francisco's extensive experience in commercial planning, operational execution, and team building to guide Eikon through late-stage clinical trials and market entry in the competitive oncology landscape.

https://briefglance.com/articles/eikon-signals-commercial-ambition-tapping-pg-veteran-for-board-seat

Moderna CLO Klinger sells $173,550 in shares

Shannon Thyme Klinger, Moderna's Chief Legal Officer, sold $173,550 worth of company common stock on June 4, 2026, as part of a Rule 10b5-1 trading plan. This transaction followed her acquisition of shares through exercised stock options and vested restricted stock units. Moderna's stock has seen a 73% return over the past year, though InvestingPro analysis suggests it may be overvalued.

https://www.investing.com/news/insider-trading-news/moderna-clo-klinger-sells-173550-in-shares-93CH-4731579

Trending Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.2% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 27.7% Today

Expedia Group Inc. ($EXPE) Stock Forecast: Down 5.2% Today

First Solar Inc. ($FSLR) Stock Forecast: Down 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 5.0% Today

FMC Corporation ($FMC) Stock Forecast: Down 5.4% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.2% Today

Cummins Inc. ($CMI) Stock Forecast: Down 5.0% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Down 5.2% Today

Innovative Industrial Properties Inc ($IIPR) Stock Forecast: Down 2.6% Today

Moderna Inc. Price History

03.05.2026 - MRNA Stock was up 7.8%

• Moderna's shares surged by 8.1% today due to positive updates, including encouraging data on a new cancer vaccine, an expanded partnership for an ebolavirus vaccine, and the launch of an e-commerce platform.
• The bullish momentum was reinforced by UBS increasing its price target for Moderna, Inc. (MRNA) in anticipation of key pipeline catalysts, reflecting confidence in the company's future.
• Despite facing scrutiny over allegations regarding the efficacy of its RSV vaccine, investors appeared more focused on the positive developments and growth opportunities in the oncology market.
• Anticipated growth in the Acute Respiratory Distress Syndrome (ARDS) market and ongoing research by industry leaders likely contributed to the positive sentiment surrounding Moderna and its mRNA technology.

03.05.2026 - MRNA Stock was up 5.5%

• Moderna (MRNA) saw a significant uptrend recently due to various factors:
• Bright prospects in the Acute Respiratory Distress Syndrome (ARDS) market, with growth projections fueled by innovative therapies being researched, potentially aligning with Moderna's unique vaccine development strategies.
• Improved valuation by UBS before key pipeline events, reflecting confidence in Moderna's future and growth potential.
• Despite ongoing challenges, optimism among investors remains high regarding Moderna's upcoming projects and regulatory milestones.
• Favorable industry sentiment in healthcare, particularly in fields like oncology and acute pain management, may have influenced the positive movement in Moderna's stock.

04.05.2026 - MRNA Stock was up 9.7%

• Moderna's stock saw a 7.49% increase as investors look forward to upcoming events, such as its involvement in crucial healthcare conferences and the release of encouraging data on its melanoma treatment.
• Optimism has been reignited around Moderna's partnership with Merck for the melanoma vaccine program, showing consistent enhancements in survival rates, fueling the stock's surge.
• The President of Moderna exercising restricted stock units (RSUs), coupled with favorable updates on the company's oncology pipeline extending beyond COVID vaccines, likely bolstered bullish sentiment, propelling the stock upward today.

04.05.2026 - MRNA Stock was up 9.2%

• Moderna's stock saw a notable increase today after a period of declines, as investors are eagerly awaiting important updates from the company.
• Optimism has been reignited surrounding Moderna's collaboration with Merck on a melanoma vaccine program, with encouraging data releases contributing to the stock's upward movement.
• Investor sentiment may have been bolstered by insider activities, including the exercising of RSUs by the company's President and CFO, signaling confidence in Moderna's future growth prospects.
• Anticipation is high due to Moderna's upcoming involvement in key healthcare conferences and the unveiling of promising data related to its melanoma treatment, which has further stimulated investor interest and pushed the stock price up.

04.05.2026 - MRNA Stock was up 5.0%

• The positive outlook on Moderna's future, particularly in mRNA technology and vaccine advancements, likely drove the stock's bullish trajectory.
• A recent SEC filing suggesting a share sale by an individual may have been perceived as a routine financial action, minimally impacting the market movement.
• In contrast to Ultragenyx (RARE) facing stock declines post-disappointing earnings, Moderna's robust market performance signals strong investor confidence in its growth potential and continued success.
• Market optimism stemming from reports of Deutsche Bank's increased price target for Star Bulk Carriers (SBLK) and potential in tech stocks may have bolstered overall positive sentiment, positively influencing Moderna's stock.

05.05.2026 - MRNA Stock was down 5.3%

• Moderna (MRNA) stock declined amid profit-taking following recent positive data on its personalized mRNA-based cancer vaccine.
• An individual's proposed sale of 3471 shares via an SEC filing potentially influenced the stock's downward trend.
• Despite encouraging updates on its cancer vaccine and past successful trials, investor response may have been dampened by the insider selling activity.
• The combination of profit-taking, insider selling, and general market sentiment likely contributed to Moderna's bearish performance today.

29.04.2026 - MRNA Stock was up 5.1%

• Moderna's bullish movement today can be attributed to the positive sentiment surrounding its innovative mRNA technology and ongoing developments in the healthcare sector.
• The FDA advisory panel's recommendation to update COVID-19 vaccines for the XFG variant for the 2026-27 season could have boosted investor confidence in Moderna's capabilities to adapt to evolving virus strains.
• Despite insider selling and a cautious Wall Street sentiment, the potential for premium pricing and accelerated global market access for Moderna's plant-based drug targeting BPH and prostate cancer prevention could have sparked investor optimism.
• The acquisition of shares by institutional investors like Seven Grand Managers LLC further indicates confidence in Moderna's long-term growth prospects, potentially contributing to the bullish movement.

28.04.2026 - MRNA Stock was down 5.2%

• The bearish movement in Moderna's stock today can be attributed to:
• Perceived overbought conditions and technical indicators signaling reversals, leading traders to take short positions.
• Concerns about the stock being fundamentally overvalued, especially after its recent inclusion in the S&P 500 index.
• Lack of significant positive news catalysts to sustain the recent bullish momentum.
• Despite the bearish movement, the upcoming FDA advisory committee review for Moderna's mRNA flu shot and the company's preparations for a COVID-19 booster vaccine targeting the XFG strain in 2026–27 could potentially drive positive sentiment and future price movements.

09.05.2026 - MRNA Stock was down 5.0%

• The authorization granted to Moderna and the University of Oxford to initiate a Phase 1/2 study on an mRNA cancer vaccine for individuals with Lynch syndrome did not appear to have a positive impact on the stock price. This lack of significant effect might suggest that investors were anticipating more substantial news to influence the market.
• The selling of shares by Moderna's Chief Legal Officer, Shannon Thyme Klinger, could have contributed to the negative market sentiment. This insider trading activity might have been perceived as a signal of uncertainty regarding the company's future outlook.
• Despite noteworthy advancements in cancer vaccine trials and the appointment of a seasoned professional from Procter & Gamble to Eikon Therapeutics' Board of Directors, the focus on the Chief Legal Officer's share selling could have overshadowed these developments. This focus possibly swayed the stock's downward trajectory.
• An analysis hinting at Moderna's stock being potentially overvalued by InvestingPro may have further fueled the bearish sentiment. This suggestion might have prompted investors to reassess their positions, potentially triggering a sell-off.

20.04.2026 - MRNA Stock was up 5.1%

• Moderna's stock surged by 20% due to emerging hantavirus cases, showcasing the market's confidence in the company's pandemic defense capabilities.
• The hantavirus scare not only boosted Moderna's stock but also highlighted the potential changes in vaccine-related regulatory environments, which could further benefit the company.
• Despite concerns about declining sales and profitability, Moderna's focus on infectious disease platforms and potential vaccine developments seems to have overshadowed these worries, driving the bullish movement in its stock today.

19.04.2026 - MRNA Stock was down 5.1%

• Moderna's bearish movement today may be linked to an insider sale by President Stephen Hoge, potentially unsettling investors and adding to stock volatility.
• The market sentiment around mRNA technology and the company's need to stabilize revenue post-pandemic could be contributing to the downward trend, despite positive growth from international partnerships and new vaccines.
• Investors may also be reacting to potential legal risks from intellectual property disputes, as mentioned in a recent conference audio transcript, which might be impacting Moderna's stock performance.
• The company's strong clinical and regulatory progress, beneficial for its long-term prospects, may not be sufficient to counter the immediate market factors influencing today's bearish movement.

19.04.2026 - MRNA Stock was down 6.9%

• Moderna's stock faced a downward trend subsequent to an insider selling 53,336 shares, conducted by President Stephen Hoge. This transaction heightened stock volatility, indicating investor sensitivity to internal activities.
• The market's adverse response to the insider sale potentially reflects uncertainties about Moderna's future growth trajectory and stability post-pandemic.
• Investor focus remains on Moderna's vaccine demand, progress in pipeline projects, and endeavors to stabilize revenue, all pivotal in determining stock performance.
• Noteworthy advancements from Wave Life Sciences regarding its AATD trial possibly impacted the biotech sector positively, while Moderna's descent was influenced by the insider transaction.